Abstract
The Cheung Glutamatergic Regimen (CGR) is an experimental, low-cost oral treatment approach intended to reproduce selected features of ketamine’s rapid antidepressant and plasticity-enhancing effects by using readily available medications and nutraceuticals. In its usual form, the regimen combines low-dose dextromethorphan, generally 30-45 mg, with a CYP2D6 inhibitor such as low-dose fluoxetine, paroxetine, bupropion, or goldenseal root, together with piracetam at 600-1,200 mg; L-glutamine may be added in some cases. Across a series of hypotheses, case reports, and mechanistic papers published or posted between 2025 and 2026, Ngo Cheung proposed the regimen as a way of targeting the NMDA-AMPA glutamate axis in disorders thought to involve impaired synaptic plasticity, including refractory obsessive-compulsive disorder, treatment-resistant depression, bipolar depression, residual ADHD symptoms, trauma-related syndromes, and somatic preoccupations (Cheung, 2025g, 2026b). This manuscript reviews the scientific rationale for the regimen, starting protocols, dose-adjustment strategies, adjunctive options, safety considerations, and the early clinical evidence, including two peer-reviewed Cureus case reports and wider naturalistic observations involving more than 50 patients in routine practice. Across these reports, improvement was often described within days to weeks and in some cases appeared durable with maintenance dosing, although the evidence remains uncontrolled and preliminary. The absence of randomized trials, the need for individualized medical supervision, and the importance of future controlled and possibly genomics-informed research are central limitations. CGR is not a substitute for established treatments and should be considered, if at all, only under direct clinical oversight.